Invokana - Safe Treatment For Diabetes Or Defective Drug?
Drug companies rush new drugs to market in order to maximize profits. Often, new drugs are approved and sold without adequate testing. For diabetes, several past drugs have harmed patients. Is the new drug Invokana a safe treatment for diabetes? Or, is it a defective and dangerous drug?
What Is Invokana?Invokana (canagliflozin) is a new drug marketed as a treatment for Type 2 diabetes. It is the first drug in a new class of medications known as sodium-glucose cotransporter 2 (SGLT2) inhibitors. These drugs also include Farxiga, Glyxambi, Xigduo XR, and Jardiance. How do SGLT2 inhibitors work? They work by affecting kidney function to stop reabsorption of glucose into the patient's bloodstream. Instead, sugar is excreted through urine.
What Is The Status Of Invokana Approval And Sales?In March 2013, the FDA approved Invokana. Since then, Invokana sales have increased rapidly. Johnson & Johnson markets the drug. According to forecasts, the company may earn $1 Billion in annual sales from its new blockbuster medication.
Is Invokana Safe?Although a very recent drug, Invokana has already been linked to hundreds of adverse event reports. These include reports of kidney damage/failure, urinary tract infections, and ketoacidosis. In May 2015, the FDA issued a drug safety communication warning patients about the risk of ketoacidosis from Invokana and the other drugs in its class. Diabetic ketoacidosis is a build-up of acid in the blood. It is a serious condition that can lead to diabetic coma or even death. What are some symptoms of ketoacidosis? Symptoms include confusion, abdominal pain, difficulty breathing, unusual fatigue/sleepiness, vomiting, or nausea. In the first year the drug was sold, QuarterWatch Report identified 457 serious adverse event reports. This likely represents only a small percentage of the problems truly related to the medication. Most problems are not fully reported by medical professionals.